Free Essay

Gsk Patents

In: Business and Management

Submitted By txwdbat
Words 383
Pages 2
Through analyzing the competitors of GSK, including Merck, AstraZeneca, Pfizer, Eli Lilly, Roche, Sanofi. We found that AstraZeneca and Pfizer are the biggest threats for GSK in many areas such as Respiratory, CNS disorders etc. Therefore, we compared GSK with these two companies to evaluate the competitive advantages of GSK.

USD $ in millions, translated from GBP £ | | Dec 31, 2012 | Dec 31, 2011 | Dec 31, 2010 | Dec 31, 2009 | Dec 31, 2008 | | Land and buildings | 10,538 | 9,654 | 9,263 | 9,457 | 8,506 | | Plant, equipment and vehicles | 16,105 | 15,454 | 15,550 | 16,361 | 15,020 | | Assets in construction | 3,056 | 3,148 | 3,343 | 3,523 | 3,330 | | Property, plant and equipment, cost | 29,699 | 28,255 | 28,156 | 29,340 | 26,857 | | Accumulated depreciation | (15,427) | (14,663) | (14,234) | (14,184) | (12,708) | | Property, plant and equipment, net book value | 14,272 | 13,592 | 13,922 | 15,156 | 14,149 |

Patents 2013年数据 Assignee | No. of patent families | No. of patent families as 1st assignee | GLAXOSMITHKLINE (UK) | 37 | 32 | SANOFI-AVENTIS (FR) | 21 | 20 | US GOVERNMENT (US) | 21 | 12 | WYETH CORP (US) | 20 | 15 | NOVARTIS CORP (CH) | 19 | 13 | MERCK AND CO INC (US) | 15 | 14 | SEPPIC SA (FR) | 12 | 9 | BISEIBUTSU KAGAKU KENKYUSHO (JP) | 11 | 10 | KITASATO INST (JP) | 8 | 6 | PFIZER CORP (US) | 8 | 6 | AQUILA BIOPHARM INC (US) | 8 | 4 | UNIVERSITY OF CALIFORNIA (US) | 7 | 5 | EISAI CO LTD (JP) | 7 | 6 | STATENS SERUMINSTITUT (DK) | 6 | 6 | ANVAR (FR) | 6 | 6 | CHEMO-SERO THERAPEUTICS RESEARCH INSTITUTE (JP) | 6 | 2 | CSL LTD (AU) | 6 | 5 | DUKE UNIVERSITY (US) | 6 | 6 | AKZO NOBEL NV (NL) | 6 | 6 | GENEXINE INC (KR) | 5 | 3 | UNIVERSITY ZHEJIANG (CN) | 5 | 5 | IST SUPERIORE SANITA (IT) | 5 | 5 | PF MEDICAMENT (FR) | 5 | 3 | UNIVERSITY FUDAN (CN) | 5 | 5 | UNIVERSITY NEW YORK (US) | 5 | 5 | ANTIGENICS INC (US) | 8 | | CHEMO SERO THERAPEUT RES INST (JP) | 6 | | PF MEDICAMENT (FR) | 5 | | Totals | 279 | 209 |

In 2012, GSK disclosed that our IRR on R&D spend was approximately 12%

MANAGEMENT SKILL * Design of new seating plan---50 million dollars each product line you don’t need to schedule a meeting to share ideas—which could take a month. You just lean over and start talking. And these informal interactions spark creative energy.” *

Similar Documents

Premium Essay


...INTELLECTUAL PROPERTY(IP)-This refers to the creations of mind: invetions, literary and artistic works and symbols, names, images and designs used in commerce and trade. IP is divided into two categories- 1-Industrial Property-which includes inventions (Patents, Trademarks, Industrial Designs and Geographical Indications of source) 2-Copyright-which includes literary and artistic works such as novels, poems and plays, films, musical works, artistic works such as drawings, paintings, photographs and sculptures and architectural designs. WHAT ARE IPR’s? Intellectual Property Rights are the rights given to people over the creations of their minds. With rights in hand, through the exploitation of IP, the individuals or the business organizations earn profits either through manufacturing or licensing and which is a reward for their innovative efforts. It also acts as a stimulus to R&D efforts. NEED FOR IPR’S: Michael Porter in his work on “Competitive Advantage” stated that differentiation is a key to business competitiveness. This can achieved through product, experience, technology or way the things are performed and exhibited to satisfy the customers. However, all this amounts to the knowledge which, in today’s highly dynamic and competitive business environment is the key source of competitive strength to the organizations. The need of IPR can be felt because any invention is the intellectual catpital of a firm or an individual which needs to be captured,......

Words: 2571 - Pages: 11

Premium Essay

Gsk Case

...1- Derive three opportunities and three threats for GSK by first making the PESTEL analysis of the macro-environment surrounding the pharmaceutical industry. (9 points) * PESTEL analysis of the pharmaceutical industry: Political: Since the creation of healthcare insurance, companies have to conform themselves to two kinds of systems: 1) The universal system applied for example in France, with less demand in new technologies. 2) The very selective anglo-saxon system which is looking for high technologies, excluding people who can pay for treatments. As we know the industry have to work on growing political focus on healthcare. Indeed, global governments are looking for healthcare savings especially in this time of economic crisis. Furthermore, as the European Union is trying to harmonize healthcare between its 27 members, pharmaceutical companies will have to introduce reference in pricing and to deal with increasing pressure on pricing. Economic: Due to the context of global economic crisis, the main threat for the industry stands in the reluctance of consumers to spend on healthcare. Like most of the sectors, pharmaceutical industry copes with a reduction in its growth, even if the market perspectives are positive. To emphasize: pharmaceutical growth is following the GDP growth. Social: As the over-65’s consume 4 time more than other citizens, the aged population represents an opportunity for the pharmaceutical companies which will have to respond to......

Words: 1150 - Pages: 5

Premium Essay

Gsk Case Study

...CASE STUDY: GSK (GlaxoSmithKline) Warm-up: • Do you think that we should prevent pharmaceutical firms applying for patents? • Selling drugs online has become a common practice. Do you believe we should go further in this direction? • Is the wave of M&A beneficial for clients in the pharmaceutical industry? Question 1: Derive three opportunities and three threats for GSK by first making the PESTEL analysis of the macro-environment surrounding the pharmaceutical industry. PESTEL analysis of the macro-environment surrounding the pharmaceutical industry: As a reminder: Macro-environment: PESTEL Industry (or sector): 5 forces of Porter + Life cycle THE PESTEL MODEL: 1. Political 2. Social 3. Environmental 4. Economic 5. Techonological 6. Legal SOCIAL FACTORS Ageing population: need more drugs Better informed customers: Firms should give more information, because when you’re sick the first thing you think of doing is looking up on the internet. Firms have to work on their communication Social responsibility: related to medications that are meant to cure people. How much money should be made from drugs that are saving lives? At which point should firms renounce to their huge benefits? Importance of emerging markets: some regions in Asia More: New industries for new diseases, geographical differences (some countries don’t have money to spend on drugs) ECONOMIC FACTORS Globalisation: market is going global concerning drugs and pharmaceutical......

Words: 925 - Pages: 4

Premium Essay

Case Study Gsk

...GSK Gary Benillouche Sylvain Descazeaud Stéphane Nooroya Yousra Zaghdoud Bernichi Case C : GSK 1 - Derive three opportunities and three threats for GSK by first making the PESTEL analysis of the macro-environment surrounding the pharmaceutical industry. |Political |Economic |Social | |Governments are looking for reduce healthcare|The current economic crisis. |Population is getting older. | |costs. | | | | |Cost structure at ethical pharmaceutical |Increasing awareness of people thanks to the | |There is no convergence of healthcare system |companies: manufacturing of goods (25%), R&D |Internet : new demand and changing | |: people don't get always reimbursed their |(12 to 21%), administration (10%), sales and |expectation. | |health costs around the world. |marketing (25%). | | | | |Rise in the number of obese people. | | |New kind of competition with generics drugs. | ...

Words: 1254 - Pages: 6

Premium Essay

Gsk Pakistan- Case Analysis

...chances of survival in the industry. • The risk aversive nature of the industrialists works as a major hindrance to entry. With the absence of required finances, lack of economies of scale and stiff competition, the prospective pharmaceuticals manufacturers find the chances of flourishing in Pharmaceuticals industry very grim. Hence, avoid entering the Pharmaceuticals scene. • Only the companies with satisfactory quality and the ability to export their products will be able to carve a place for themselves. Therefore, the new entrants must keep in mind the necessity of producing quality controlled products. • Government is also providing support to the local potential entrants; incentives, lowering of import duties and relaxation in patent laws being some. Threat of Substitutes The major threat faced by Pakistan’s pharmaceutical industry is that of WTO. The fast approaching deadline resulting in the removal of trade barriers will cause an influx of medicine and other Pharmaceutical goods from Korea and European countries. These products are not only of lower price, but also of good quality, and will prove to be a good substitute for our locally manufactured products. Pakistan’s drug industry is greatly threatened by the presence of smuggled products in the market. These products, smuggled from Burma, China, India, Bangladesh etc, in ever increasing quantities, are not only cheap, but also make wild claims of increase in physical strength in just two days, or......

Words: 6008 - Pages: 25

Premium Essay

Gsk Company Profile

...GlaxoSmithKline company profile Francis Weyzig Amsterdam, October 2004 Summary Business description GlaxoSmithKline (GSK) is one of the world’s largest research-based pharmaceutical corporations that discovers, develops, manufactures and markets branded human health products. Headquarters: UK, with additional operational headquarters in the USA Global presence: about 160 countries Primary markets: USA, France, Germany, UK, Italy and Japan Employees: approximately 103,000 GSK key figures for 2003 (in £ million) Sales 21,441 Materials and production costs 4,188 Marketing and administration 7,563 R&D expenditures 2,770 Operating income 6,920 Net profit 4,765 GSK has two main business divisions, pharmaceuticals and consumer healthcare. This profile deals with the pharmaceuticals division, which generates 85% of GSK’s sales. The five largest selling GSK products are Seretide/Advair for asthma and Chronic Obstructive Pulmonary Disease (COPD); Paxil/Seroxat and Wellbutrin, both antidepression drugs; Avandia/Avadamet for type 2 diabetes; and the antibiotic Augmentin. Each of these drugs generated above £800 million of sales in 2003. GSK produces a broad range of products of special importance to developing countries, including: Anti-malaria drugs Zentel (albendazole), for de-worming and the prevention of lymphatic filariasis Pentosam, against leishmaniasis Anti-retrovirals (ARVs) for the treatment of HIV/AIDS Tuberculosis drugs Vaccines for developing......

Words: 18642 - Pages: 75

Premium Essay

Gsk, a Merger Too Far?

...Strategic Management Case study C: GSK, a merger too far? Answer 1: 1. By using Five Force Framework, assess the threat of rivalry and threat of entry in the pharmaceutical industry: Threats of rivalry. When we talk about threats of rivalry we should mention not only the rivalry at the industry but also at the product market level. Industry level The pharmaceutical industry has become increasingly concentrated during last 20 years. Guided by absence of proper R&D facilities, gradual expiry of patents and other reasons, there has been a number of mergers and acquisitions in the industry within last 20 years. This trend is currently shaping the internal rivalry among companies. The major reasons for that are opportunistic financial operations and the creation of synergy. It is worth mentioning that some companies would prefer to merge than to experience hostile takeover. Product market level: The two-tier structure has to be taken into account: patented original brands vs. generics. Original compete mostly on non-price benefits, especially as long as they are patent protected, whereas generic drug are generally driven by price competition. The threats of entry. The threats of entry into the pharmaceutical industry are extremely high. Still, it is considered to be very attractive for the new comers. As an evidence for that, 21 pharmaceuticals are featured in the Fortune 500 companies in return on sales. The pharmaceutical industry has big barriers to prevent new comers......

Words: 1222 - Pages: 5

Premium Essay


...11 February 2015 Intellectual property: Case study PATENTS First, I would make my own research about if there are already existing products that may be similar to my invention. If I would be very sure of the novelty of the product, I would go to the National patent office in Latvia, fill in the legal documents and register for the patent grant. However, already at this point I would meet the first risk – the procedure what to demand from the lawyers. Knowing the specific matters about the Patent office of Latvia, I would consult about what should be done to gain the maximum information and protection from registering the patent. Due the fact that prior arts are a global matter, the issue should be demanded to be researched prom the lawyer’s side so that in future less problems can arise. It is important to remember that the application form would clearly form the problem that has been solved, public’s interest in finding a solution of this problem and the novelty of the solution itself. Also point out that the product will be used in any kind of industries (for example, security service/ life guards in mountains etc.). It is very important to educate the reader about the matter of the patent due the fact that misinterpretation could lead to the failure of the registration, for example, if the application focuses on the design approach of the scarf rather than the unusual manner or procedure etc., it may accrue that application is rejected as being identified as an......

Words: 403 - Pages: 2

Premium Essay

Accounting Gsk

...pharmaceutical manufacturers only account for 15% of the market share. The most important issue faced by large pharmaceutical companies globally is the expiration of their patents, which results in the production of generic drugs by other manufacturers at lower price. The last 4 years companies have faced a series of simultaneous patent expiries, leading to severe sales losses of up to $250 billion from 2012 until today. Lastly, global trade and regulations have an impact on pricing controls, which has led companies to alter their portfolios from primary-care blockbusters to specialties (IBIS). Pfizer Inc. (600 words) Pfizer, Inc. is the largest player in the global pharmaceutical industry, with an estimated market share of 4.2%. Pfizer is a research-based pharmaceutical company, which operates in 3 segments, Global Innovative Pharmaceutical (GIP), Global Established Pharmaceutical (GEP) and Vaccines, Oncology and Consumer Healthcare (VOC) (Exhibit 4). Table 1: Pfizer Inc. revenues 2012-2014 | 2014 | 2013 | 2012 | Revenues (in billions $) | 49.6 | 51.6 | 54.6 | % change | -3.84% | -5.62% | -10.45% | Source: Pfizer Annual Reports 2014 As shown in Table 1, Pfizer’s revenues dropped by 5.62% in 2013 followed by another drop by almost 4% in 2014. Pfizer’s revenue was negatively affected by the expiration of patents for major products in their portfolio and unfavourable foreign exchange rates (Pfizer Annual Reports 2014). Over 92% of the total Revenue for 2014 was......

Words: 3225 - Pages: 13

Premium Essay

Gsk and Access to Essential Medicines

...of their shareholders. Contradictory statements were made by CEO, J P Garnier which suggested that they are looking to make profits for their shareholders, which led to a questionable integrity. GlaxoSmithKline (GSK) has been putting in a lot of effort to improve the healthcare in Less Developed Countries (LDCs) and in Sub-Saharan Africa. Their substantial effort has shifted to investing in research and development (R&D) of diseases which is necessary in the developing nations since they heavily rely on external support due to the inadequate facilities and is not self-sufficient in regards to developing medicines for the diseases themselves. The less developed regions are the ones that are significantly impacted, hence GSK has taken the initiative to set preferential pricing arrangements to benefit these regions. GSK has also continued with its philanthropic deeds by continuing programs that cares for, supports and educate the locals about HIV/AIDS in 27 different countries. Another altruism act that is performed by GSK is the donation that it carries out. It donated 100 million preventative treatments as part of its commitment to eradicate Lymphatic Filariasis, which is a disease caused by parasitic worms. With the shareholders kept in mind, GSK has to ensure that it is making enough profits in order to compensate the shareholders, as well as to consider the LDCs who cannot afford the medicines at regular prices, hence causing a conflict of interest where the...

Words: 3288 - Pages: 14

Premium Essay

Financial Statement Analysis of Gsk

...| SumiAkterRitu | 20-030 | | | | | Prepared for: | Tanvir Hamim | Lecturer | Department of Banking and Insurance | Faculty of Business Studies | University of Dhaka | | Date of Submission: June 15th, 2015. Table of contents Sl. No. | Particulars | Page | 1. | Introduction 1.1 Background of the study 1.2 Objective of the study 1.3 Scope of the study 1.4 Metholodgy of the study 1.5 Limitation of the study | 6-766677 | 2. | Organizational overview2.1 GSK Bangladesh 2.2 Mission, strategic intent & spirit of GSK Bangladesh2.3 Quality statement | 8-118-91011 | 3. | Analysis of financial statement of GSK Ltd. GlaxoSmithKline Bangladesh Limited | 12-15 | 4. | Ratio analysis of GSK limited company | 16-28 | 5. | Conclusion | 29 | 6. | Reference | 30 | Letter of Transmittal To Tanvir Hamim Lecturer Department of Banking and Insurance University of Dhaka Subject: Submission of Report on “Analysis of Financial Statement GSK”. Dear Sir, We would like to thank you for the guidance and support you have provided us during the course of this report. Without your help, this report would have been impossible to complete. To prepare the report we collected what we believe to be most relevant information to make our report as analytical and reliable as possible. We have concentrated our best effort to achieve the objectives of the report. The practical knowledge and experience gathered by us during report preparation will......

Words: 4743 - Pages: 19

Premium Essay

Supply Chain Sustainability at Gsk

...avoid actions that reduce the ability of the interested parties, including the future generations to meet their needs. In order to elaborate, how a leading global organization takes Sustainable Supply Chain Management as a strategic goal, we have prepared our report on GSK’s Sustainability elements. GSK is one of the world’s leading research-based pharmaceutical and healthcare companies, developing and supplying medicines to a huge global market. The company employs more than 97,000 people in over 100 countries and has an extensive worldwide supply chain. GSK’s mission is to help people do more, feel better, live longer. They do this through investing in R&D, adopting flexible approaches to pricing, promoting open innovation, and strengthening healthcare systems. By growing their business and extending access to their medicines, GSK ensures long term commercial success as well as creating value for its shareholders and delivering economic benefits to the wider society. GSK contributes directly and indirectly to the economic growth in more than 150 countries through tax, charitable support and employment of 101,255 people around the world. This report reflects the actions taken up by GSK for achieving sustainability in their supply chain operations. GSK’S top 10 sustainability successes have also been highlighted in this report as to how they achieved the Carbon Trust Certification, reduced Carbon footprint, reduced the use of water, Zero Waste and the collaboration they......

Words: 4386 - Pages: 18

Premium Essay

Gsk a Merger Too Far

...GSK, a merger too far? 1- Analyse these two forces : * Threat of entry : Very important * Very high expenses on advertising Direct to Consumer (DTC) * In this industry some specific skills to manufacture drugs are required, because they need to pass severe clinical trials before being commercialized. * It can take a very long time to become profitable and to compensate the speeding in R&D. * The whole industry has a bad reputation because of former issues so it is difficult to have a positive image. * Also, you need numerous sales representatives to have a real impact on the market and to get a global commercial reach. * Threat of rivalry : important * Even niches areas in this industry are more and more crowded. * The top 10 pharmaceutical firms stand for 50% of the global sales. * There is he generic competition from which branded drugs producers are suffering. Indeed when the lifetime of a patent is over , generic companies rush to the market and offer drugs with the same active components but in a very low cost. There is also a real competition between generic companies. * Medium-sized pharmas have to consider M&A as a survival strategy. 2- Which factors explain the wave of mergers and acquisitions in the pharmaceutical industry? The pharmaceutical industry is a really special one, on the contrary of the most part of industries there is very few new products coming to market. Indeed, a lot of money and a......

Words: 951 - Pages: 4

Premium Essay

Gsk Merger

...Headquartered in the UK and having listing on both New York stock exchange and London stock exchange. GSK is one of the industry leaders, with an estimated seven per cent of the world's pharmaceutical market; GSK is the only pharmaceutical company researching both medicines and vaccines for the World Health Organization’s three priority diseases HIV/AIDS, tuberculosis and malaria. GSK employs over 100,000 people, has more than 80 manufacturing sites in 37 countries, and makes almost four billion packs of medicines and healthcare products each year. GSK spends £8 million (US$14 million) on research and development each day – that’s around £300,000 (US$562,000) every hour (GlaxoSmithKline, 2008). Moreover in 2007 the turnover decreased from 23.2 % in 2006 to 22.7 % a very challenging year for the company as GSK unexpectedly faced a severe decline in sales of Avandia, the second biggest product (GlaxoSmithKline, 2007). 2. Glaxo Wellcome Glaxo originates in New Zealand, where it was founded in 1873 by Joseph Nathan. Glaxo already knows the merger game as before Glaxo welcome was created in 1995 when Glaxo took over Wellcome for £9bn, in what was then the biggest merger in UK corporate history. Wellcome Foundation was financing medical research and was established in 1936, welcome owned a 40% stake in Zantac, Glaxo struggled to find a replacement for its blockbuster, whose patent has expired in the US, and for Zovirax, Wellcome's anti-herpes drug which has already......

Words: 1304 - Pages: 6

Premium Essay

Financial Analysis Gsk

...Latha Ramesh Submitted By: Yateendra Agarwal Registration No: 1220344 Section: D Batch: 2012-2014 Christ University Institute of Management Kengri Campus Established in the year 1924 in India GlaxoSmithKline Pharmaceuticals Ltd. (GSK Rx India) is one of the oldest pharmaceuticals company and employs over 3500 people. Globally, GSK is a £ 27.4 billion, leading, research-based healthcare and pharmaceutical company. In India, it is one of the market leaders with a turnover of Rs. 2699 crore and a share of 4.2%. The GSK India product portfolio includes prescription medicines and vaccines. Our prescription medicines range across therapeutic areas such as anti-invectives, dermatology, gynaecology, diabetes, oncology, cardiovascular disease and respiratory diseases. The company is the market leader in most of the therapeutic categories in which it operates. GSK also offers a range of vaccines, for the prevention of hepatitis A, hepatitis B, invasive disease caused by H, influenza, chickenpox, diphtheria, pertussis, tetanus, rotavirus, cervical cancer, streptococcus pneumonia and others.GSK's best-in-class field force, backed by a nation-wide network of stockists, ensures that the Company's products are readily available across the nation. GSK has two manufacturing units in India, located at Nashik and Thane as well as a clinical development centre in Bangalore. The state of art plant at Nashik makes formulations while bulk drugs and the active pharmaceutical ingredients......

Words: 3823 - Pages: 16